Sangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $27.29 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.